Analysis of incidence trend of thyroid cancer in Baoshan District, Shanghai from 2000 to 2022

doi:10.16150/j.1671-2870.2024.04.005

Abstract

Abstract:

Objective To provide a scientific basis for the prevention and control of thyroid cancer by analyzing the incidence characteristics and trends of thyroid cancer in Baoshan District, Shanghai from 2000 to 2022. Methods The thyroid cancer incidence data from the Shanghai Cancer Registry Reporting System from 2000 to 2022 were used to analyze the incidence of thyroid cancer among registered residents of Baoshan District. Indices such as crude incidence rate, age-standardized incidence rate (ASIR), cumulative incidence rate for ages 0-74, truncated rate for ages 35-64, and age-specific and gender-specific incidence rates were calculated using Excel 2013.Joinpoint 5.0.2.0 software was used to calculate the annual percentage of change (APC) and average annual percentage of change (AAPC), and to conduct trend analysis. Results Between 2000 and 2022, a total of 6 877cases of thyroid cancer were monitored and recorded in Baoshan District,with an average annual incidence rate of 33.38/100 000(ASIR of 28.77/100 000), among which the incidence rate for males was 17.54/100 000 (ASIR of 15.40/100 000), and for females was 49.87/100 000 (ASIR of 43.05/100 000);the cumulative incidence rate for the 0-74 age group was 2.16%;and the truncated rate for the 35-64 age group was 64.07/100 000. The ASIR of thyroid cancer showed an overall upward trend over the 23 years, with an AAPC of 14.51% (P<0.001). It increased rapidly from 2000 to 2017, with an APC of 20.79% (P<0.001), followed by a stabilization phase from 2017 to 2022, with an APC of -4.50% (P=0.146). The incidence rate of thyroid cancer reached two peaks in in the 30-34 and 55-59 age groups, with the incidence rates of 45.37/100 000 and 52.12/100 000, respectively. The incidence trend of all age groups showed that the average increase rate was the highest between 20 and 44 years old, with an AAPC of 17.02% (P<0.001). Conclusions The incidence of thyroid cancer in Baoshan District of Shanghai presentes a shift from a rapid to a stable trend, yet it remains at a relatively high level. There is a need for further investigation into the causes of the high incidence of thyroid cancer. The age groups of 30-34 and 55-59 should be particularly emphasized as key focus populations, and targeted prevention strategies must be developed to mitigate their risk.

Key words: Thyroid cancer, Incidenc rate, Annual percent change, Incidence trends

CLC Number:

R736.1

ZHANG Zhiping, CAI Shilong, GENG Yanlong, LIU Shiyou. Analysis of incidence trend of thyroid cancer in Baoshan District, Shanghai from 2000 to 2022[J]. Journal of Diagnostics Concepts & Practice, 2024, 23(04): 378-384.

Figures/Tables 6

Table 1

Table 2

Figure 1

Figure 2

Table 3

Figure 3

References 31

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.
[3]	HAN B, ZHENG R, ZENG H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53.
[4]	鲍萍萍, 吴春晓. 上海市癌症流行现况和防治实践[J]. 上海预防医学, 2020, 32(11):955-962.
	BAO P P, WU C X. Epidemiology, control and prevention of cancers in Shanghai[J]. Shanghai J Prev Med, 2020, 32(11):955-962.
[5]	许海瑞, 石野宽, 黄晓红, 等. 碘难治性分化型甲状腺癌的医学影像学研究进展[J]. 安徽医学, 2024, 45(3):380-384.
	XU H R, SHI Y K, HUANG X H, et al. Advances in medical imaging of iodine-resistant differentiated thyroid cancer[J]. Anhui Med J, 2024, 45(3):380-384.
[6]	周峰, 吴春晓, 郑莹, 等. 1981—2010年上海市市区甲状腺癌的发病趋势[J]. 环境与职业医学, 2015, 32(11):997-1002.
	ZHOU F, WU C X, ZHENG Y, et al. Temporal trend of thyroid cancer incidence in Urban Shanghai, 1981-2010[J]. J Environ Occup Med, 2015, 32(11):997-1002.
[7]	王烨菁, 王飞, 高淑娜, 等. 上海市黄浦区1973—2013年大肠癌发病情况分析[J]. 环境与职业医学, 2016, 33(4):325-328.
	WANG Y J, WANG F, GAO S N, et al. Analysis on colorectal cancer incidence in Huangpu District of Shanghai, 1973-2013[J]. J Environ Occup Med, 2016, 33(4):325-328.
[8]	高艳多, 阎炯, 赵胜, 等. 1990—2019年中国女性乳腺癌发病和死亡趋势的年龄-时期-队列模型分析[J]. 中国预防医学杂志, 2022, 23(12):909-916.
	GAO Y D, YAN J, ZHAO S, et al. Trends in incidence and mortality of female breast cancer in China from 1990 to 2019 using age-period-cohort analysis model[J]. Chin Prev Med, 2022, 23(12):909-916.
[9]	National Cancer Institute. Average annual percent change(AAPC)[EB/OL].[2023-12-15]. http://surveillance.cancer.gov/joinpoint/aapc.html.
[10]	汪亚萍, 景文展, 杜敏, 等. “一带一路”沿线国家HIV/AIDS流行现状及变化趋势研究[J]. 中华流行病学杂志, 2022, 43(7):1053-1059.
	WANG Y P, JING W Z, DU M, et al. Epidemic situation of HIV/AIDS and change trend in Belt and Road countries[J]. ChinJ Epidemiol, 2022, 43(7):1053-1059.
[11]	MIRANDA-FILHO A, LORTET-TIEULENT J, BRAY F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study[J]. Lancet Diabetes Endocrinol, 2021, 9(4):225-234.
[12]	罗亭亭, 孟迪, 张华, 等. 2010—2017年青岛市居民甲状腺癌发病与死亡分析[J]. 中华肿瘤防治杂志, 2019, 26(17):1231-1236.
	LUO T T, MENG D, ZHANG H, et al. Analysis of thyroid cancer incidence and death among Qingdao residents from 2010 to 2017[J]. Chin J Cancer Prev Treat, 2019, 26(17):1231-1236.
[13]	林艺兰, 林福生, 陈国伟, 等. 2011—2018年厦门市甲状腺癌流行趋势和生存率分析[J]. 现代预防医学, 2021, 48(16):2897-2899,2937.
	LIN Y L, LIN F S, CHEN G W, et al. Epidemiological trend and survival analysis of thyroid cancer in Xiamen from 2011 to 2018[J]. Mod Prev Med, 2021, 48(16):2897-2899,2937.
[14]	马晶昱, 相智声, 林永添, 等. 2011—2020年福建省肿瘤登记地区甲状腺癌流行特征及变化趋势[J]. 实用肿瘤学杂志, 2023, 37(4):301-307.
	MA J Y, XIANG Z S, LIN Y T, et al. Epidemic characteristics and changing trends of thyroid cancer in cancer registration areas of Fujian province from 2011 to 2020[J]. Pract Oncol J, 2023, 37(4):301-307.
[15]	鲍萍萍, 吴春晓, 张敏璐, 等. 2015年上海市恶性肿瘤流行特征分析[J]. 中国癌症杂志, 2019, 29(2):81-99.
	BAO P P, WU C X, ZHANG ML, et al. Report of cancer epidemiology in Shanghai, 2015[J]. Chin Oncol, 2019, 29(2):81-89. doi: 10.19401/j.cnki.1007-3639.2019.02.001
[16]	苏幸, 郑琳, 章华米, 等. 2010—2020年浙江省杭州市西湖区甲状腺癌发病特征和流行趋势分析[J]. 疾病监测, 2022, 37(10):1367-1370.
	SU X, ZHENG L, ZHANG H M, et al. Thyroid cancer incidence trend in Xihu district,Hangzhou,2010-2020[J]. Dis Surveill, 2022, 37(10):1367-1370.
[17]	FIORE M, OLIVERI CONTI G, CALTABIANO R, et al. Role of emerging environmental risk factors in thyroid cancer: a brief review[J]. Int J Environ Res Public Health, 2019, 16(7):1185.
[18]	霍诗睿, 王伟, 王欣榕, 等. 环境因素对中国不同地区甲状腺癌发病率的影响分析[J]. 肿瘤影像学, 2022, 31(5):463-470.
	HUO S R, WANG W, WANG X R, et al. The impact of environmental factors on thyroid cancer in different regions of China[J]. Oncoradiol, 2022, 31(5):463-470.
[19]	张洁, 闫贻忠, 王丹, 等. 2005—2014年中国肿瘤登记地区甲状腺癌发病的时间趋势分析[J]. 现代预防医学, 2020, 47(4):577-582,591.
	ZHANG J, YAN Y Z, WANG D, et al. Time trend analysis of thyroid cancer incidence in tumor registration areas of China from 2005 to 2014[J]. Mod Prev Med, 2020, 47(4):577-582,591.
[20]	裘凤黔, 杜娟, 纪云芳, 等. 2002—2017年黄浦区甲状腺癌发病趋势[J]. 预防医学, 2022, 34(1):83-86.
	QIU F Q, DU J, JI Y F, et al. Trends in incidence of thyroid cancer in Huangpu District from 2002 to 2017[J]. Prev Med, 2022, 34(1):83-86.
[21]	HALL S F, IRISH J, GROMME P, et aL. Access, excess, and overdiagnosis: the case for thyroid cancer[J]. Cancer Med, 2014, 3(1):154-161.
[22]	AHN H S, KIM H J, WELCH H G. Korea's thyroid-cancer “epidemic”--screening and overdiagnosis[J]. N Engl J Med, 2014, 371(19):1765-1767.
[23]	中华医学会内分泌学分会, 中华医学会外科学分会甲状腺及代谢外科学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南(第二版)[J]. 中华内分泌代谢杂志, 2023, 39(03):181-226.
	Chinese Society of Endocrinology,Thyroid and Metabolism Surgery Group of the Chinese Society of Surgery, China Anti-Cancer Association, et al. Guidelines for the diagnosis and management of thyroid nodules and differentiated thyroid cancer (Second edition)[J]. Chin J Endocrinol Metab, 2023, 39(03):181-226.
[24]	中国抗癌协会甲状腺癌专业委员会CATO. 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J]. 中国肿瘤临床, 2016, 43(10):405-411.
	Thyroid Cancer Professional Committee of China Anti Cancer Association. Chinese expert consensus on diagnosis and treatment of thyroid micropapillary carcinoma(2016)[J]. Chin J Clin Oncol, 2016, 43(10):405-411.
[25]	KILFOY B A, ZHENG T, HOLFOR T R, et al. International patterns and trends in thyroid cancer incidence, 1973-2002[J]. Cancer Causes Control, 2009, 20(5):525-531.
[26]	MANNATHAZHATHU A S, GEORGE P S, SUDHAK-ARAN S, et al. Reproductive factors and thyroid cancer risk: Meta-analysis[J]. Head Neck, 2019, 41(12)4199-4208.
[27]	KIM H, KIM K Y, BAEK J H, et al. Are pregnancy, pa-rity, menstruation and breastfeeding risk factors for thyroid cancer? Results from the Korea National Health and Nutrition Examination Survey, 2010-2015[J]. Clin Endocrinol (Oxf), 2018, 89(2):233-239.
[28]	SUNG H, SIEGEL R L, TORRE L A, et al. Global patterns in excess body weight and the associated cancer burden[J]. CA Cancer J Clin, 2019, 69(2):88-112.
[29]	陈夏怡, 周玲燕, 陈晨, 等. 甲状腺微小乳头状癌消融治疗的现状及进展[J]. 中国临床研究, 2023, 36 (11):1613-1618.
	CHEN X Y, ZHOU L, CHEN C, et al. Recent status and advances of ablation for papillary thyroid microcarcinoma[J]. Chin J Clin Res, 2023, 36 (11): 1613-1618.
[30]	张玉亮, 朱宏, 陈德轩, 等. 甲状腺结节病例特点分析及其临床诊治意义[J]. 中国临床研究, 2023, 36 (11): 1619-1622.
	ZHANG Y L, ZHU H, CHEN D X, et al. Characteristics of thyroid nodule cases and its clinical significance for dia-gnosis and treatment[J]. Chin JClin Res, 2023, 36 (11): 1619-1622.
[31]	王杨凤, 刘君. 2016—2020年涪陵区甲状腺癌发病趋势[J]. 预防医学, 2022, 34(5):511-514.
	WANG Y F, LIU J. Trends in incidence of thyroid cancer in Fuling District from 2016 to 2020[J]. J Prev Med, 2022, 34(5):511-514.

Gender	case	proportion（%）	Crude rate (1/10⁵)	ASIR(1/10⁵)	Cumulative rate (0-74 years old) (%)	Truncated rate(35-64 years old) (1/10⁵)
Total	6 877	100.00	33.38	28.77	2.16	64.07
Male	1 843	26.80	17.54	15.40	1.13	41.32
Female	5 034	73.20	49.87	43.05	3.30	87.65

Gender	Period	APC				AAPC
Gender	Period	%	95%CI	t vale	P vale	%	95%CI	t vale	P vale
male	2000—2017	21.17	18.58-23.82	18.67	<0.001	15.44	13.09-17.84	13.68	<0.001
	2017—2022	-2.10	-8.11-4.30	-0.70	0.491
female	2000—2018	19.16	16.68-21.68	7.57	<0.001	13.02	10.4-15.70	10.25	<0.001
	2018—2022	-10.91	-19.44-1.47	-2.41	0.027
total	2000—2017	20.79	18.19-23.45	18.21	<0.001	14.51	12.17-16.91	12.83	<0.001
	2017—2022	-4.50	-10.38-1.78	-1.52	0.146

Age/year	APC				AAPC
Age/year	Period	%	95%CI	P vale	%	95%CI	P vale
20-44
Total	2000—2017	23.18	19.57-26.90	<0.001	17.02	13.91-20.20	<0.001
	2017—2022	-1.72	-8.95-6.07	0.638
Male	2000—2016	25.34	20.81-30.05	<0.001	18.40	15.01-21.88	<0.001
	2016—2022	1.69	-4.04-7.76	0.551
Female	2000—2018	21.33	18.16-24.59	<0.001	15.66	12.48-18.93	<0.001
	2018—2022	-6.75	-16.71-4.41	0.210
45-64
Total	2000—2014	22.04	19.39-24.75	<0.001	12.61	9.94-15.25	<0.001
	2014—2020	4.62	0.40-9.03	0.034
	2020—2022	-20.02	-35.12-1.41	0.038
Male	2000—2016	18.53	15.59-21.55	<0.001	13.28	10.64-16.00	<0.001
	2016—2022	-2.88	-9.6-4.34	0.403
Female	2000—2014	22.32	18.85-25.90	<0.001	12.14	8.62-15.77	<0.001
	2014—2020	3.09	-2.27-8.73	0.243
	2020—2022	-21.45	-40.66-3.99	0.087
≥65
Total	2000—2015	23.01	18.94-27.23	<0.001	14.88	11.18-18.71	<0.001
	2015—2019	8.06	-4.47-22.23	0.200
	2019—2022	-11.46	-20.99-0.78	0.038
Male	2000—2018	15.27	9.42-21.43	<0.001	9.93	4.46-15.69	<0.001
	2018—2022	-11.18	-26.46-7.27	0.204
Female	2000—2015	24.05	19.83-28.42	<0.001	15.65	11.78-19.67	<0.001
	2015—2019	7.52	-5.70-22.59	0.257
	2019—2022	-10.21	-20.04-0.82	0.066